Ziftomenib

Overview

Ziftomenib is a small molecule active pharmaceutical ingredient (ChEMBL CHEMBL5095038).

Patent & exclusivity (US)

Per the FDA Orange Book (1 approved US product), the latest listed US patent on Ziftomenib expires 16 Jul 2044 and exclusivity 13 Nov 2030. Generic API sourcing typically opens up once these lapse.

Chemical identity

IUPAC name

4-methyl-5-[[4-[[2-(methylamino)-6-(2,2,2-trifluoroethyl)thieno[2,3-d]pyrimidin-4-yl]amino]piperidin-1-yl]methyl]-1-[(2S)-2-(4-methylsulfonylpiperazin-1-yl)propyl]indole-2-carbonitrile

Canonical SMILES

CC1=C(C=CC2=C1C=C(N2C[C@H](C)N3CCN(CC3)S(=O)(=O)C)C#N)CN4CCC(CC4)NC5=C6C=C(SC6=NC(=N5)NC)CC(F)(F)F

InChIKey

BGGALFIXXQOTPY-NRFANRHFSA-N